… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … Medicines Symposium on June 29, 2022 as part of the RNAEditing track. The Company’s presentation will be webcast …
… company dedicated to changing lives through transformative RNA therapies, today announced several presentations … highlighting the Company’s proprietary Axiomer ® RNAediting technology platform at upcoming scientific and …
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Further strengthened leading intellectual property (IP) position with issuance of new patent in the United S
… company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a … event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline …
… to changing lives through the creation of transformative RNA therapies, today announced that Company management will … to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Company …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre